No Data
No Data
No Data
No Data
No Data
Why We're Not Concerned About Sipai Health Technology Co., Ltd.'s (HKG:314) Share Price
It's not a stretch to say that Sipai Health Technology Co., Ltd.'s (HKG:314) price-to-sales (or "P/S") ratio of 1x right now seems quite "middle-of-the-road" for companies in the Consumer Retailing i
Simply Wall StMay 2 20:46 ET
Spike Health (00314) subsidiary further subscribes to China Construction Bank wealth management products with a capital of 100 million yuan
Spai Health (00314) announced that on April 16, 2024, Shipai Health Industry Investment, a wholly-owned subsidiary of the company, has subscribed to wealth management products with a capital of 100 million yuan provided by China Construction Bank. On April 24, 2024, Spai Health Industry Investment further subscribed to wealth management products with a capital of 100 million yuan provided by China Construction Bank.
Zhitong FinanceApr 24 05:49 ET
SIPAI HEALTH: 2023 Annual Report
Futu NewsApr 12 05:07 ET · Announcements
[Hong Kong Stock Connect] The net loss of Spike Health (00314) narrowed sharply to RMB 256 million last year
Jinwu Financial News | Spai Health (00314) announced that in 2023, the company achieved a loss attributable to parent company owners of 256 million yuan (RMB, same below), a sharp decrease over the previous year; the basic loss per share was 0.4 yuan, compared to 12.19 yuan in the same period last year. During the period, the company achieved revenue of 4.712 billion yuan, an increase of 14.4% year on year; gross profit of 415 million yuan, an increase of 22.9% year on year. By business, the company's specialty pharmacy business revenue was 4.188 billion yuan, up 14.4% year on year; doctor research assistance business revenue was 362 million yuan, up 13.3% year on year; health insurance services
金吾財訊Mar 19 08:47 ET
Sipai Health (00314.HK)'s annual revenue of 4.71 billion yuan increased 14.4% year-on-year
Gelonghui, March 19 | Spai Health (00314.HK) announced that for the year ended December 31, 2023, the company's revenue was 4.71 billion yuan, up 14.4% year on year; adjusted net loss was 150 million yuan, compared with a loss of 259 million yuan for the same period last year. The gross margin increased slightly from about 8.2% in 2022 to about 8.8% in 2023, mainly reflected in a sharp increase in the gross margin of the doctor research assistance service business and the relative stability of the gross margin of the health insurance service business.
Gelonghui FinanceMar 19 08:21 ET
SIPAI HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 19 08:15 ET · Announcements
No Data
No Data